Literature DB >> 19074020

Matrix metalloproteinase-9 facilitates glial scar formation in the injured spinal cord.

Jung-Yu C Hsu1, Lilly Y W Bourguignon, Christen M Adams, Karine Peyrollier, Haoqian Zhang, Thomas Fandel, Christine L Cun, Zena Werb, Linda J Noble-Haeusslein.   

Abstract

In the injured spinal cord, a glial scar forms and becomes a major obstacle to axonal regeneration. Formation of the glial scar involves migration of astrocytes toward the lesion. Matrix metalloproteinases (MMPs), including MMP-9 and MMP-2, govern cell migration through their ability to degrade constituents of the extracellular matrix. Although MMP-9 is expressed in reactive astrocytes, its involvement in astrocyte migration and formation of a glial scar is unknown. Here we found that spinal cord injured, wild-type mice expressing MMPs developed a more severe glial scar and enhanced expression of chondroitin sulfate proteoglycans, indicative of a more inhibitory environment for axonal regeneration/plasticity, than MMP-9 null mice. To determine whether MMP-9 mediates astrocyte migration, we conducted a scratch wound assay using astrocytes cultured from MMP-9 null, MMP-2 null, and wild-type mice. Gelatin zymography confirmed the expression of MMP-9 and MMP-2 in wild-type cultures. MMP-9 null astrocytes and wild-type astrocytes, treated with an MMP-9 inhibitor, exhibited impaired migration relative to untreated wild-type controls. MMP-9 null astrocytes showed abnormalities in the actin cytoskeletal organization and function but no detectable untoward effects on proliferation, cellular viability, or adhesion. Interestingly, MMP-2 null astrocytes showed increased migration, which could be attenuated in the presence of an MMP-9 inhibitor. Collectively, our studies provide explicit evidence that MMP-9 is integral to the formation of an inhibitory glial scar and cytoskeleton-mediated astrocyte migration. MMP-9 may thus be a promising therapeutic target to reduce glial scarring during wound healing after spinal cord injury.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19074020      PMCID: PMC2712293          DOI: 10.1523/JNEUROSCI.2287-08.2008

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  66 in total

1.  The chondroitin sulfate proteoglycans neurocan and phosphacan are expressed by reactive astrocytes in the chronic CNS glial scar.

Authors:  R J McKeon; M J Jurynec; C R Buck
Journal:  J Neurosci       Date:  1999-12-15       Impact factor: 6.167

2.  Neurocan is upregulated in injured brain and in cytokine-treated astrocytes.

Authors:  R A Asher; D A Morgenstern; P S Fidler; K H Adcock; A Oohira; J E Braistead; J M Levine; R U Margolis; J H Rogers; J W Fawcett
Journal:  J Neurosci       Date:  2000-04-01       Impact factor: 6.167

3.  Increased chondroitin sulfate proteoglycan expression in denervated brainstem targets following spinal cord injury creates a barrier to axonal regeneration overcome by chondroitinase ABC and neurotrophin-3.

Authors:  James M Massey; Jeremy Amps; Mariano S Viapiano; Russell T Matthews; Michelle R Wagoner; Christopher M Whitaker; Warren Alilain; Alicia L Yonkof; Abdelnaby Khalyfa; Nigel G F Cooper; Jerry Silver; Stephen M Onifer
Journal:  Exp Neurol       Date:  2007-04-12       Impact factor: 5.330

4.  Intraspinal microinjection of chondroitinase ABC following injury promotes axonal regeneration out of a peripheral nerve graft bridge.

Authors:  Veronica J Tom; John D Houlé
Journal:  Exp Neurol       Date:  2008-02-14       Impact factor: 5.330

5.  Hyaluronan-CD44 interaction stimulates Rac1 signaling and PKN gamma kinase activation leading to cytoskeleton function and cell migration in astrocytes.

Authors:  Lilly Y W Bourguignon; Eli Gilad; Karine Peyrollier; Amy Brightman; Raymond A Swanson
Journal:  J Neurochem       Date:  2007-03-30       Impact factor: 5.372

6.  MMP-2 and MMP-9 increase the neurite-promoting potential of schwann cell basal laminae and are upregulated in degenerated nerve.

Authors:  T A Ferguson; D Muir
Journal:  Mol Cell Neurosci       Date:  2000-08       Impact factor: 4.314

7.  Matrix metalloproteinase-2 facilitates wound healing events that promote functional recovery after spinal cord injury.

Authors:  Jung-Yu C Hsu; Robert McKeon; Staci Goussev; Zena Werb; Jung-Uek Lee; Alpa Trivedi; Linda J Noble-Haeusslein
Journal:  J Neurosci       Date:  2006-09-27       Impact factor: 6.167

8.  Matrix metalloproteinase-2 (MMP-2) regulates astrocyte motility in connection with the actin cytoskeleton and integrins.

Authors:  Crystel Ogier; Anne Bernard; Anne-Marie Chollet; Thierry LE Diguardher; Stephen Hanessian; Gérard Charton; Michel Khrestchatisky; Santiago Rivera
Journal:  Glia       Date:  2006-09       Impact factor: 7.452

9.  Bradykinin induces matrix metalloproteinase-9 expression and cell migration through a PKC-delta-dependent ERK/Elk-1 pathway in astrocytes.

Authors:  Hsi-Lung Hsieh; Cheng-Ying Wu; Chuen-Mao Yang
Journal:  Glia       Date:  2008-04-15       Impact factor: 7.452

Review 10.  Metalloproteinases in biology and pathology of the nervous system.

Authors:  V W Yong; C Power; P Forsyth; D R Edwards
Journal:  Nat Rev Neurosci       Date:  2001-07       Impact factor: 34.870

View more
  69 in total

1.  Matrix metalloproteinase-9 and -2 expression in the olfactory bulb following methyl bromide gas exposure.

Authors:  Stephen R Bakos; James E Schwob; Richard M Costanzo
Journal:  Chem Senses       Date:  2010-06-07       Impact factor: 3.160

Review 2.  Metzincin proteases and their inhibitors: foes or friends in nervous system physiology?

Authors:  Santiago Rivera; Michel Khrestchatisky; Leszek Kaczmarek; Gary A Rosenberg; Diane M Jaworski
Journal:  J Neurosci       Date:  2010-11-17       Impact factor: 6.167

3.  Matrix metalloproteinase-9 controls proliferation of NG2+ progenitor cells immediately after spinal cord injury.

Authors:  Huaqing Liu; Veronica I Shubayev
Journal:  Exp Neurol       Date:  2011-07-02       Impact factor: 5.330

4.  Low-Dose and Short-Duration Matrix Metalloproteinase 9 Inhibition Does Not Affect Adhesion Formation during Murine Flexor Tendon Healing.

Authors:  Caitlin A Orner; Michael B Geary; Warren C Hammert; Regis J O'Keefe; Alayna E Loiselle
Journal:  Plast Reconstr Surg       Date:  2016-03       Impact factor: 4.730

5.  Spinal Glia Division Contributes to Conditioning Lesion-Induced Axon Regeneration Into the Injured Spinal Cord: Potential Role of Cyclic AMP-Induced Tissue Inhibitor of Metalloproteinase-1.

Authors:  Huaqing Liu; Mila Angert; Tasuku Nishihara; Igor Shubayev; Jennifer Dolkas; Veronica I Shubayev
Journal:  J Neuropathol Exp Neurol       Date:  2015-06       Impact factor: 3.685

6.  Prevention of both neutrophil and monocyte recruitment promotes recovery after spinal cord injury.

Authors:  Sang Mi Lee; Steven Rosen; Philip Weinstein; Nico van Rooijen; Linda J Noble-Haeusslein
Journal:  J Neurotrauma       Date:  2011-08-08       Impact factor: 5.269

7.  Matrix metalloproteinase-9-null mice are resistant to TGF-β-induced anterior subcapsular cataract formation.

Authors:  Anna Korol; Giuseppe Pino; Dhruva Dwivedi; Jennifer V Robertson; Paula A Deschamps; Judith A West-Mays
Journal:  Am J Pathol       Date:  2014-05-06       Impact factor: 4.307

Review 8.  Molecular dissection of reactive astrogliosis and glial scar formation.

Authors:  Michael V Sofroniew
Journal:  Trends Neurosci       Date:  2009-09-24       Impact factor: 13.837

9.  Deficiency in matrix metalloproteinase-2 results in long-term vascular instability and regression in the injured mouse spinal cord.

Authors:  Alpa Trivedi; Haoqian Zhang; Adanma Ekeledo; Sangmi Lee; Zena Werb; Giles W Plant; Linda J Noble-Haeusslein
Journal:  Exp Neurol       Date:  2016-07-25       Impact factor: 5.330

10.  Rescue of impaired fracture healing in COX-2-/- mice via activation of prostaglandin E2 receptor subtype 4.

Authors:  Chao Xie; Bojian Liang; Ming Xue; Angela S P Lin; Alayna Loiselle; Edward M Schwarz; Robert E Guldberg; Regis J O'Keefe; Xinping Zhang
Journal:  Am J Pathol       Date:  2009-07-23       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.